We only have this paper's title and publication details.
Read it at the source: SCFM is a significant prognosis factor of stage IV NSCLC treated by nivolumab.
No takes yet. Share an insight, caveat, or question.
Popinat et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: